A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS

S. N. Scelsa; D. J.L. MacGowan; H. Mitsumoto; T. Imperato; A. J. LeValley; M. H. Liu; M. DelBene; M. Y. Kim

doi:10.1212/01.WNL.0000156913.24701.72

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS

S. N. Scelsa, D. J.L. MacGowan, H. Mitsumoto, T. Imperato, A. J. LeValley, M. H. Liu, M. DelBene, M. Y. Kim

Epidemiology & Population Health

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.

Original language	English (US)
Pages (from-to)	1298-1300
Number of pages	3
Journal	Neurology
Volume	64
Issue number	7
DOIs	https://doi.org/10.1212/01.WNL.0000156913.24701.72
State	Published - Apr 12 2005

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/01.WNL.0000156913.24701.72

Cite this

@article{6f74e13a543e48728053bcad92b0ae95,

title = "A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS",

abstract = "There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.",

author = "Scelsa, {S. N.} and MacGowan, {D. J.L.} and H. Mitsumoto and T. Imperato and LeValley, {A. J.} and Liu, {M. H.} and M. DelBene and Kim, {M. Y.}",

year = "2005",

month = apr,

day = "12",

doi = "10.1212/01.WNL.0000156913.24701.72",

language = "English (US)",

volume = "64",

pages = "1298--1300",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS

AU - Scelsa, S. N.

AU - MacGowan, D. J.L.

AU - Mitsumoto, H.

AU - Imperato, T.

AU - LeValley, A. J.

AU - Liu, M. H.

AU - DelBene, M.

AU - Kim, M. Y.

PY - 2005/4/12

Y1 - 2005/4/12

N2 - There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.

AB - There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.

UR - http://www.scopus.com/inward/record.url?scp=16844384316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844384316&partnerID=8YFLogxK

U2 - 10.1212/01.WNL.0000156913.24701.72

DO - 10.1212/01.WNL.0000156913.24701.72

M3 - Article

C2 - 15824372

AN - SCOPUS:16844384316

SN - 0028-3878

VL - 64

SP - 1298

EP - 1300

JO - Neurology

JF - Neurology

IS - 7

ER -

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this